lacutamab,vimseltinib,fosifloxuridine nafalbenamide,ngm120,rly-4008,onvansertib
cardiff oncology,innate,nucana,deciphera,ngm biopharmaceuticals,relay therapeutics
['rly-4008', 'nuc3373', 'onvan', 'lacuta', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'vimseltinib', 'ngm120', '$ngm', '$ipha', '$ncna', '$rlay']
#esmo22 pres. tom. (9/11) $crdf onvansertib ph1/2 (#mcrc)
$rlay rly-4008 ph1 (#cholangiocarcinoma)
$ngm ngm120 ph1 (#solidtumors)
$ipha lacutamab ph1b (#tcelllymphoma)
$dcph vimseltinib ph2 (#tgct)
$ncna nuc3373 ph2 (#crc) see our blog for all pres. 
FDA Catalyst Calendar, Big Mover™ stocks to watch, & Model Portfolios. 

Database & tools to make you a profitable biotech stock investor. Try Free https://t.co/5njnanqtbK